Several anti-angiogenic molecules (e.g., the anti-vascular endothelial growth factor (VEGF) monoclonal antibodies bevacizumab, brivanib, dovitinib, nintedanib, etc.)are currently used in the treatment of various cancers, including HCC, suggesting that angiogenesis is a promising therapeutic target [85,86,87]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.